Lec 18- Parkinsons Flashcards

1
Q

Motor disorders of the basal ganglia

A
  • Parkinson’s
    • Hypokinetic disorder (Akinesia and rigidity) often associated with tremor
  • Huntington’s disease- Hyperkinetic disorder- chorea
  • Ballism/Hemiballism
    • Hyperkinetic disorder
  • Basal ganglia= collection of 6 nuclei that controls our voluntary movement
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Parkinsons I

A
  • 1817 James Parkinson- shaking palsy
  • Progressive disorder
  • Muscle rigidity
  • Akinesia- difficulty in initiating movement
  • Resting involuntary tremor- simulates pill rolling
  • Slow shuffling gait
  • Dementia
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Parkinsons II

A
  • 0.1% of population, disease of the elderly
  • >50yrs- 1% of population
  • Mean survival time after diagnosis- 10yrs
  • Drug therapy improves clinical symptoms but does not alter disease progression
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Parkinson’s Disease III

A
  • Specific loss of DA cells in the substantia nigra pars compacta
  • Loss of dopaminergic nigrostriatal pathway- idiopathic stroke, viral infection
  • Parkinsonism- drug-induced, amphetamines, neuroleptics
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)

A
  • Irreversible selective destruction of nigro-strial neurones
  • Frozen adddict syndrome
  • Converted to MPP+ by MAO B and uptake by specific DA transporter system
  • Inhibits mitochondrial oxidation reaction- oxidative stress
  • Useful experimental tool
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Pathology

A
  • In early-onset Parkinson’s- there is a specific gene mutation
  • Leads to the presence of Lewy bodies- aggregates of proteins that build up inside nerves, contribute to dementia
    • Contain a-synuclein
  • Parkin, ubiquitin, LRRK2, PINK
  • Defective disposal of these proteins may render cells susceptible to oxidative stress
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

The Basal Ganglia

A
  • Six interconnected nuclei
    • The striatum, GPe, GPi, STN-only glutamatergic nuclei, site of deep brain stimulation, SNr, SNc
  • Integrates motor and sensory information from the cortex before relaying it back to the cortex via the thalamus
  • Many parallel loop circuits, not all strictly ‘motor’ (also sensory even emotional (limbic) loops)= Parallel processing hypothesis
  • The output from the BG is controlled by two parallel but opposing pathways which are modulated by DA
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Dopaminergic modulation of basal ganglia output- (DIRECT PATHWAY)

A
  • Cerebral cortex- Both paths start this way (DIRECT PATHWAY)
    • Sends excitatory glutaminergic paths to basal ganglia
    • Striatum (input stations) receives excitatory signal
    • Striatum neurones are GABAergic (inhibitory) reduce excitation to Substania nigra, GPi (these are the output stations)
    • SNr/GPi (also GABAergic) send inhibitory signals to the thalamus
      • SNr/GPi (Output stations) inhibit thalamocortical motor loop
    • SNc (substania nigra compacta) releases DA, acts on D-1 project to output stations, postsynaptic receptors causes excitatory action (increases Adenylate cyclase and cAMP)
      *
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Dopaminergic modulation of basal ganglia output (INDIRECT)

A
  • Cerebral cortex excites the Striatum
  • Striatum inhibits GPe cells
  • GPe inhibits STN (subthalamic Nucleus)
  • STN excitatory (glutaminergic) neurones stimulate SNr/GPi
  • There is an excitatory feedback loop between SNr/GPi and GPe
  • SNc releases DA in the (striatum) onto D2-receptors (inhibitory), the cells containing D2 project to GPe
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

The BG and motor dysfunction

A
  • Arises through an imbalance between the direct and indirect pathways => motor dysfunction
  • Hypokinetic disorders: Parkinson’s disease
  • Hyperkinetic movement disorders e.g. Huntingtons, ballism
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Parkinson’s

A
  • Primary pathology is the loss of nigrostriatal dopaminergic pathway
    • => excessive inhibition of the thalamocortical pathway
    • We lose excitation of the direct pathway
  • May explain (to an extent)
  • Akinesia (the absence or reduction of movement
  • Bradykinesia (slowness of movement)
  • Rigidity (resistance to passive movement)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

In Parkinson’s- Dopaminergic modulation of basal ganglia- Direct pathway

A
  • For direct pathway
    • We lose DA, so no released by SNc
    • No excitation of the striatum (so no adenylate cyclase => cAMP => No AP, Ca influx and Ca-dependent exocytosis) so reduced GABA release
    • SNr/GPi then get excited (no GABA released onto them), these cells then release EXCESS GABA onto the thalamocortical motor loop
    • Excessive inhibition of thalamocortical loop gives symptoms of Parkinson’s (Reduced Voluntary movement)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Dopaminergic modulation of basal ganglia output- INDIRECT

A
  • SNc has reduced DA released so less D2 neuronal stimulation
  • Less inhibition of striatum which increases GABA release= Increased inhibition of GPe
  • GPe is inhibited so less GABA is released onto STN (excited)
  • Increased activity of STN neurones, STN are glutaminergic which excites output stations (SNr/GPi)
  • Excessive stimulation of SNr/GPi causes increased release of GABA
  • Excess release of GABA causes increased inhibition of thalamocortical motor loop
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Current research- neuronal synchronisation is the key

A
  • The rate and pattern of neuronal firing encodes information in the BG
  • DA depletion induces bursting firing and synchronisation of BG neuronal firing
  • Neuronal Oscillations at the beta frequency (20Hz) correlate with bradykinesia
  • Oscillatory activity in the cortex and the STN-GP network has been implicated in pathological disorders
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Surgical treatments

A
  • Pallidotomy or subthalamotomy
  • Thalamotomy- excessive bradykinesia
  • Deep brain stimulation of subthalamic nucleus (STN) @130Hz
    • Gets rid of pathological oscillations
  • Direct non-invasive stimulation of the motor cortex
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Assessment of symptoms

A
  • UPDRS III- unified Parkinson’s disease rating scale (5 sections including self and clinical rated evaluation)
  • Cared Assessment
  • ADL- activities of daily living (self-reported)
17
Q

Drug therapy

A
  • UK Guidelines Parkinson’s disease consensus working group 1998
  • Loss of DA upsets balance of excitation provided by DA and ACh systems
  • Most therapies aimed at replacing or replenishing dopaminergic neurotransmission or reducing ACh action at muscarinic receptors
  • Secondary changes in 5-HT, GABA, peptides (enkephalin) in the nigra and GPe
  • Choice of therapy depends on age, symptoms, cognitive impairment, other illnesses
18
Q

Anti-muscarinics

A
  • Early (mild) stage
  • Help in tremor (not hypokinesia or ridigity )
  • Useful in secondary Parkinsonism (neuroleptic-induced)- cant use L-DOPA= psychosis and schizophrenia
  • Benztropine, biperiden
  • Troublesome side effects, best avoided in elderly patients
19
Q

L-DOPA (Di-hydroxy phenylalanine)

A
  • First line treatment- oral administration (crosses BBB) 250mg-8g DD 1.5 hr half-life (TDS)
  • Usually given in combination with peripheral dopa decarboxylase inhibitor carbidopa 500mg-1g BD or TDS (SINEMET or SINEMET CR)
  • L-DOPA and benserazide (MADOPAR)
  • Initially 80% of patients show improvement 20% become normal
20
Q

L-DOPA side effects

A
  • Dyskinesia- Unpredictable motor complications (extrapyramidal)
  • Wearing off effects- Effectiveness declines with time
  • Progressive On-Off (swinging)- On periods complicated by dyskinesias and off periods severely akinetic
  • Neuropsychiatric side effects- Schizo-like syndrome e.g. hallucinations
  • Nausea and vomiting, anorexia, hypotension
  • symptoms of therapy or disease progression?
  • Accelerate degenerative process- oxidative stress
  • Does reducing L-DOPA exposure really reduce disease progression
21
Q

The mechanism for L-DOPA induce dyskinesia

A
  • Short acting t1/2
  • Dosage
  • Age of PD onset
  • Severity of PD
22
Q

Combined therapies

A
  • L-dopa sparing strategy- aimed at reducing the effective dose of L-dopa
  • +Dopa-decarboxylase inhibitors- carbidopa, benserazide
  • +DA agonists- Bromocriptine, pramipexole
  • +COMT inhibitor- entacapone
  • +MAO-B inhibitors- Selegiline
  • +DA releasers- Amantadine
  • +ACh antagonists- Benztropine
23
Q

Dopamine agonist

A
  • Not as effective as L-DOPA initially
  • Evidence for less on/off fluctuation
  • Monotherapy (bromocryptine PARLODEL x3 or barbegoline x1) Also in connection with L-DOPA (Pramipexole x3, Ropinirole x3)
  • Alternative to L-DOPA in younger patients?- Less side effects
  • Expensive
24
Q

Apomorphine

A
  • DA agonist
  • Administered by injection
  • Rescue treatment for sudden on/off periods
  • Works within 5-15 minutes
  • Often used as a rescue treatment
25
Q

COMT Inhibitor

A
  • The catechol-o-methyl-transferase enzyme involved in the metabolism of DA i.e. allows more L-DOPA to enter the brain
  • Used as adjunct therapy- prolong L-DOPA half-life
  • Reduces [plasma] fluctuations
  • Entacapone (COMTAN 200mg tab taken with L-DOPA dosage) May require 10-30% L-Dopa dose reduction
  • Additional side effects- diarrhoea discoloured urine
  • Tolcapone (TASMAR) withdrawn due to fatal liver damage
26
Q

MAO-B inhibitors and DA releasers

A
  • MAO-B inhibitors - selegiline (only neuroprotective treatment) (ELDEPRYL)
    • 5mg tablets < 10mg per day
    • Neuroprotective?? but little evidence
    • Side effects hallucinations and confusion
    • FATAL INTERACTION with opioids
    • Mild antidepressant - avoid with TCAs & SSRIs
  • DA releasers - amantadine (SYMMETREL)
    • Gelatin capsule or syrup
    • enhance release, block uptake
    • anticholinergic effect
    • NMDA antagonism- LTP (reduced cognitive ability)
    • useful in early treatment for rigidity and end-stage dyskinesia
  • Side effects confusion, lightheadedness, red spiders web mottling of legs
27
Q

Alternative treatments

A
  • Fetal-nigral (striatal) transplantation
  • Green tea, smoking, cannabis, ecstasy (?? roles in oxidative stress)
  • Use of stem cells
    • The embryonic stem cell that matures into a DA neurone
    • Ethical issues of embryonic research
    • Adult stem cells- New neurones
  • Gene therapy
28
Q

Gene Therapy

A
  • Insertion of genes into an individual’s cells and tissues
  • Extra, correct copies of genes are provided to complement the loss of function
  • Viruses bind to their hosts and introduce their genetic material into the host cell as part of their replication cycle
  • In PD- A neuroprotective strategy
29
Q
A
  • AAV-hAADC-2 (Genzyme)
    • L-DOPA to DA, no side effects, Phase I trial
  • AAV-GAD (Neurologix)
    • Intrasubthalamic, Phase I results positive, Phase II recruiting
  • TH, AADC, GTP cyclohydroxylase (Prosavin)
    • Lentivirus, 3 genes, converts cells to DA producing
    • no side effects
  • GDNF (Cere120, Neurturin)
    • AAAV Lentiviral vector into BG gene expression without toxicity.
    • Neurotrophic factors for dopamine cells